Combination Therapy with Anti-CTLA-4
<p>Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy</p>
... therapeutic combination in cancer treatment depends on the sequence of combined-therapeutic ...between anti-CTLA-4 and Doxil occurs only when we inject anti- CTLA-4 prior ...
10
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
... with combination anti-PD-1/anti-CTLA-4 therapy showing a durable response despite possessing worse prognostic features (GNA11 mutation, older age at pres- entation, male gender, ...
8
Anti CTLA 4 therapy for malignant mesothelioma
... There was no statistically significant difference between treated patients and placebo patients, and side effects such as diarrhoea, loss of appetite, and development of rashes were seen at higher rates in treated ...
17
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA 4 therapy
... Overall, these observations suggest that although CPI-1205 treatment might enhance chemokine-mediated T cell infiltra- tion of tumors, the latter mechanism does not seem to substan- tially contribute to the enhanced ...
7
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
... ipilimumab. Combination therapy, however, is associated with significant toxicity with greater than half of patients experiencing grade 3 or 4 adverse events (Larkin et al, ...combined ...
6
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
... theory, anti-PD-1 (α-PD-1) plus anti-CTLA-4 (α-CTLA-4) treatment simultaneously block two inhibi- tory signaling pathways of anti-tumor immune response ...Besides, ...
12
Suppressing T cell motility induced by anti–CTLA 4 monotherapy improves antitumor effects
... models, anti–CTLA-4 mAbs alone fail to induce effective immune responses to poorly immunogenic tumors but are successful when combined with additional interventions, including local ionizing ...
14
Cancer vaccine formulation dictates synergy with CTLA 4 and PD L1 checkpoint blockade therapy
... with anti–CTLA-4 and anti–PD-L1 checkpoint blockade, overcoming primary resistance to check- point blockade therapy and greatly enhancing complete cure ...between ...
18
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti–PD-1/anti–CTLA-4 immunotherapy
... or CTLA-4 alone is sufficient to delay tumor growth in preclinical models of TSC and that anti–PD-1 can yield complete tumor-free ...and CTLA-4 is more effective than single-agent ...
20
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
... protein 4 (CTLA- 4) immune-inhibitory receptors (immune checkpoints) expressed mainly on T ...against CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) enhance antitumor T cell ...
10
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
... autophagy and apoptosis in different melanoma cells independent of B-RAF and N-RAS mutational status [9, 19]. In the last 10 years, promising targeted therapies have been developed for the treatment of malignant melanoma ...
10
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
... of CTLA-4 and PD-1 blockers are im- pressive durable response rates and manageable adverse events, but only a fraction of patients were seen to re- spond to monotherapy ...[13–15]. Combination of ...
12
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
... in combination with checkpoint modula- tion in this pseudometastasic model by performing TIL analysis on day 18 post-tumor implantation ...the combination of checkpoint anti- bodies was able to ...
12
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
... ICI therapy [38, ...to anti-CTLA-4 ...to anti-PD-L1 treatment was associated with transforming growth factor-β (TGF-β) signaling in fi- broblasts, and this occurred particularly in ...
10
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies.
... Although the extent of the contribution of ADCC to the activity of ipilimumab and tremelimumab has not been formally tested, our mouse model suggests that it is potentially critical and that further enhancement of ADCC ...
21
CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
... with PARP- and BRAF-/MEK-targeted therapies. Predictive biomarker tests for such combinatory thera- pies might include MAPK-pathway (RAS/RAF/MEK/ERK) and DNA repair enzyme (BRCAness) muta- tion analyses together with ...
10
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
... Citrus (cluster identification, characterization, and re- gression) is an automated algorithm designed to discover statistically significant stratifying features across known endpoints [13]. In the Citrus analysis, ...
14
POTENTIALITY OF NEWER ORAL ANTI HYPERGLYCEMIC COMBINATION THERAPY OVER CONVENTIONAL THERAPY
... However, Monotherapy is capable of maintaining a target glycemic control only for a short term. Effective management requires combination therapy that addresses both insulin resistance and beta cell ...
12
Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy
... against CTLA-4 are under study in clinical ...(42), anti-tumor associated antigen (TAA) photodynamic or sonodynamic (PS) -conjugated antibody (43), and anti-VEGFR-2scFv conjugated with ...
7
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
... receiving CTLA-4-blocking drugs achieve the objective tumor re- sponse, while most have ...in CTLA-4; some variants seem to influence the response to therapy with improved overall ...
14